News

Regulatory News:

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the "Company"), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2022 and provided a

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)

Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website

Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in

Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the

Humana Specialty Pharmacy has won the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category for the fifth year in a row. The award recognizes best-in-class customer satisfaction

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2022. Amounts, unless specified otherwise, are

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.

“This quarter, we have continued to

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022. Unless otherwise stated, all comparisons are for the

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at two healthcare conferences in May.

On Wednesday, May 11, 2022, the Company will present at the BofA

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug

Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday

Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities